Do you want to read an article? Please log in or register.
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
SPECIAL REPORT
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
SABCS 2024
Breast Cancer
Updates on ADCs in treatment of advanced breast cancer
Breast Cancer
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry
Int J Cancer
Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T
doi: 10.1002/ijc.35296
Breast Cancer
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Clin Cancer Res
Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L
doi: 10.1158/1078-0432.CCR-24-1553
Genitourinary Cancer
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Clin Cancer Res
Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR
doi: 10.1158/1078-0432.CCR-24-2850
COMMENTED
Breast Cancer
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O'Meara T, Grinda T, Morganti S, Waks AG, Winer EP, Lin NU, Krop IE, Tolaney SM, Sammons S, Lustberg M
doi: 10.1093/jnci/djaf220
Breast Cancer
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
Clin Cancer Res
Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F
doi: 10.1158/1078-0432.CCR-24-3468
Breast Cancer
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
Eur J Cancer
Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, Battaiotto E, Carnevale Schianca A, Giordano E, Katrini J, Castellano G, Taurelli Salimbeni B, Leonardi MC, Dicuonzo S, Criscitiello C, Bianco N, Dellapasqua S, Munzone E, Curigliano G, Colleoni M, Jereczek-Fossa BA
doi: 10.1016/j.ejca.2024.115164